Ipsen withdrew tazemetostat worldwide for follicular lymphoma and epithelioid sarcoma after new trial data suggested a less favorable safety profile than previously characterized. SYMPHONY-1 ...

Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik® (tazemetostat) in ...

Synovial sarcoma, a rare cancer, thrives on glutamine. Blocking its nutrient supply with the drug V9302 stops tumor growth, offering a new way to treat the disease.

Inform future clinical development plans, further establishing elraglusib as a potential backbone therapy in ...

Based on the clinical trial findings, Ipsen is withdrawing Tazverik across all indications, including both follicular lymphoma and epithelioid sarcoma, and is discontinuing all active tazemetostat ...

Dedifferentiated liposarcoma lacks effective IGF-1→PPAR-γ adipogenic signaling due to epigenetic silencing of PPAR-γ2, with ...

Confirmatory trial on tazemetostat suggested a link with secondary hematologic malignancie ...

The withdrawal stems from secondary hematologic malignancies observed in the Phase 3 SYMPHONY-1 trial in relapsed/refractory ...

Pediatric sarcomas are a significant category within pediatric malignancies, comprising over 20% of solid malignant cancers in children. These cancers are ...

In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ... Read More The post Health Check: Telix jumps first hurdle with its ...

John Cuddihy was appointed to a new body aimed at boosting public confidence in the flagship QEUH in Glasgow as a cancer ward ...